Proteomics

Dataset Information

0

Systemic LRG1 expression in melanoma is associated with disease progression and recurrence


ABSTRACT: Treatment of late-stage melanoma patients with immune checkpoint blockade (ICB) is currently one of the most effective standard therapies. The response rates upon neoadjuvant ICB in stage III melanoma are higher as compared to stage IV disease. Given that successful ICB depends on systemic immune response, we hypothesized that systemic immune suppression might be a mechanism responsible for lower response rates in late-stage disease, and also potentially with disease recurrence in early-stage disease.

INSTRUMENT(S): Q Exactive HF-X, Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Serum

DISEASE(S): Melanoma

SUBMITTER: Peter Robert Mosen  

LAB HEAD: Christian Blank

PROVIDER: PXD040399 | Pride | 2024-01-09

REPOSITORIES: Pride

altmetric image

Publications

Rural hospitals' viability and strategic responses.

Ludke R L RL   Westhoff L J LJ   Flood B M BM  

Health progress (Saint Louis, Mo.) 19920501 4


In 1989 the Catholic Health Association, in conjunction with the University of Iowa Center for Health Services Research, surveyed chief executive officers (CEOs) of rural hospitals regarding their hospital's viability and strategic behaviors and orientations. An extensive questionnaire was sent to the CEOs of all Catholic, all other religious not-for-profit, and all investor-owned rural hospitals, as well as to a 50 percent random sample of government and other not-for-profit rural hospitals. CE  ...[more]

Similar Datasets

2024-06-24 | PXD050798 | Pride
2012-06-30 | E-MTAB-796 | biostudies-arrayexpress
2024-05-23 | PXD048186 | Pride
2024-07-12 | PXD043122 | Pride
2012-10-05 | E-GEOD-37233 | biostudies-arrayexpress
2023-08-07 | PXD039648 | Pride
2024-08-28 | PXD054119 | Pride
2024-11-06 | PXD052553 | Pride
2013-01-05 | E-GEOD-42908 | biostudies-arrayexpress
2024-07-12 | PXD039896 | Pride